|
Pfizer marks a major
milestone in the fight
against antimicrobial
resistance in the UAE
(DUBAI)
-
Pfizer has announced the
introduction of a novel
treatment in the United Arab
Emirates for adult patients
with serious, Gram-negative
bacterial infections. This
milestone marks a
significant advancement in
addressing antimicrobial
resistance (AMR), a global
health challenge that
already affects millions of
people every year.
Antimicrobial resistance
occurs when bacteria and
other microbes no longer
respond to existing
medicines, making infections
harder to treat and
increasing the risk of
severe illness. Resistant
Gram-negative infections can
leave patients vulnerable
with very limited treatment
options. For patients and
their loved ones, this can
mean longer hospital stays,
greater uncertainty, and
emotional strain.
This newly introduced
therapy is designed to
restore effectiveness
against some of the most
resistant pathogens,
addressing a critical unmet
need in infectious disease
management.
Serhat Yalcinkaya, Pfizer's
Gulf Cluster Lead, said:
“At Pfizer, our
focus has always been on
patients. Today’s milestone
underscores our commitment
to delivering scientific
breakthroughs that change
patients’ lives. For more
than 175 years, Pfizer has
been at the forefront of
tackling infectious
diseases, and our continued
efforts to address
antimicrobial resistance
reflect both our
responsibility and
dedication to patients
across the Gulf region.
We are proud to
collaborate with healthcare
providers, governments, and
partners in the UAE to
ensure patients have timely
access to life-saving
treatments today while
safeguarding future
generations,” he added.
This launch is part of
Pfizer’s wider efforts to
strengthen infectious
disease preparedness in the
Gulf region by collaborating
with healthcare providers,
governments, and communities
to expand access and
safeguard patient care.
PRINT
THIS ARTICLE
|
